A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN

Summary

This is a multicenter, Phase 2 Simon 2-Stage study designed to assess the safety, tolerability, PK, and efficacy of oral zelavespib (PU-H71) administered daily in adults with accelerated phase (10% to 19% blasts in peripheral or bone marrow) myeloproliferative neoplasm, with or without ongoing concomitant treatment with ruxolitinib.

Timeline

Start

2022-06-15

Primary completion

2023-12-15

Completion

2024-02-23

Drugs

Indications